Romosozumab: Additional Ph III BRIDGE data

Additional data from the double-blind, international Phase III BRIDGE trial in 245 men with osteoporosis showed that once-monthly 210 mg subcutaneous romosozumab significantly improved BMD at the lumbar spine from baseline to 12 months, the primary endpoint, by 12.1% compared to placebo (p<0.01). On secondary endpoints, romosozumab significantly improved BMD at the femoral neck and total hip from baseline to 12 months by 2.2% and 2.5%, respectively, compared to placebo (p<0.01 for both). The partners previously reported top-line data showing that romosozumab met the primary and secondary endpoints (see BioCentury, March 28, 2016)...